Safety Profile of Cilta-Cel: Saad Z. Usmani, MD, MBA, FACP

Video

The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed adverse events in the CARTITUDE-1 trial.

This content originally appeared on our sister site, CancerNetwork®.

CancerNetwork® spoke with Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, to discuss the safety profile of the phase 1b/2 CARTITUDE-1 trial that looked at patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel). These findings were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Transcription:

For CARTITUDE-1, there were no new safety updates because the more common adverse events that we observe with CAR T-cell therapies—not just with the previously reported [B-cell maturation antigen]–directed CAR T-cells, but also with CD19 CAR T-cells—[are] hematologic AEs. Those were quite common and consistent with what has been reported in the past. The same is true for [cytokine release syndrome (CRS)]. Ninety-two patients out of the 97 had CRS, but most of those were grade 1 or grade 2, and CRS resolved in 99% of the patients within 14 days of onset.

Reference
Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021,39(suppl 15):8005. doi:10.1200/JCO.2021.39.15_suppl.8005

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
© 2025 MJH Life Sciences

All rights reserved.